跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CDK12 Inhibitor
首页
药物
CDK12 Inhibitor
CDK12 Inhibitor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE
EP 4355426 C0
申请人: CARRICK THERAPEUTICS LTD
优先权: 2021
EP
US
WO
4 件公开
Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US 9932344 B2
申请人: CANCER RESEARCH TECH LTD
优先权: 2014
US
4 件公开
Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease
US 11976334 B2
申请人: BAYER AG
优先权: 2017
CN
US
2 件公开
USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
US 20240350505 A1
申请人: REPARE THERAPEUTICS INC
优先权: 2019
CN
US
2 件公开
A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR
US 20240101707 A1
申请人: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD
优先权: 2021
CN
US
2 件公开
METHODS OF USING ATR INHIBITORS
US 20250228862 A1
申请人: REPARE THERAPEUTICS INC
优先权: 2022
CN
US
2 件公开
NOVEL CDK12/13 COVALENT INHIBITOR HAVING A FUSED RING STRUCTURE SUBSTITUENT OR PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
WO 2025176178 A1
申请人: SHANGHAI INST ORGANIC CHEMISTRY CAS
优先权: 2024
CN
WO
2 件公开
USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER
US 2024173330 A1
申请人: REPARE THERAPEUTICS INC
优先权: 2023
US
2 件公开
4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
US 11857552 B2
申请人: CARRICK THERAPEUTICS LTD
优先权: 2017
US
4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use
US 12473303 B2
申请人: CARRICK THERAPEUTICS LTD
优先权: 2019
US
第 1 / 3 页
上一页
下一页
药物
反馈